We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
HiberCell, a new startup focused on preventing cancer metastasis and relapse, launched Thursday with research out of Mount Sinai and $60.75 million from the likes of ARCH Venture Partners, Hillhouse Capital and 6 Dimensions Capital.